β受体阻滞剂治疗症状性儿童CPVT的国际多中心队列研究
该国际多中心队列纳入329例RYR2变异携带的症状性CPVT儿童,比较β1选择性阻滞剂与非选择性阻滞剂对心律失常事件风险的影响。中位随访6.7年,β1选择性组主要和次要结局风险均显著更高(HR 2.04和1.99)。结论提示应优先选用纳多洛尔,无法获取时选用普萘洛尔。
要点
- 症状性CPVT儿童中,β1选择性阻滞剂较非选择性阻滞剂增加心律失常事件风险。
- 纳多洛尔为优选β受体阻滞剂,无法获取时选用普萘洛尔。
- 阿替洛尔、比索洛尔和美托洛尔风险均高于纳多洛尔。
核心结论
- 在症状性CPVT儿童中,β1选择性β受体阻滞剂较非选择性β受体阻滞剂与更高的心律失常事件风险相关,纳多洛尔应作为首选。
研究设计与样本
- 国际多中心注册队列研究,纳入2个国际注册库中RYR2变异携带、β受体阻滞剂治疗前有晕厥或心脏骤停且起始治疗年龄<18岁的症状性CPVT儿童,共329例。
主要发现
- 中位随访6.7年(IQR 2.8-12.5),99例(30.1%)发生主要结局,74例(22.5%)发生次要结局。
- β1选择性阻滞剂较非选择性阻滞剂的主要结局HR为2.04(95%CI 1.31-3.17),次要结局HR为1.99(95%CI 1.20-3.30)。
- 与纳多洛尔相比,阿替洛尔主要结局HR 2.68(95%CI 1.44-4.99),比索洛尔HR 3.24(95%CI 1.47-7.18),美托洛尔HR 2.18(95%CI 1.08-4.40)。
- 与纳多洛尔相比,仅阿替洛尔次要结局HR升高(HR 2.68,95%CI 1.30-5.55)。
临床怎么用
- 对症状性CPVT儿童,应优先选用非选择性β受体阻滞剂纳多洛尔;若纳多洛尔不可用,则选用普萘洛尔。
- 避免将β1选择性阻滞剂(如阿替洛尔、比索洛尔、美托洛尔)作为症状性CPVT儿童的首选治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Symptomatic children with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for recurrent arrhythmic events. β-Blockers decrease this risk, but studies comparing individual β-blockers in sizeable cohorts are lacking. We aimed to assess the association between risk for arrhythmic events and type of β-blocker in a large cohort of symptomatic children with CPVT. METHODS: From 2 international registries of patients with CPVT, RYR2 variant-carrying symptomatic children (defined as syncope or sudden cardiac arrest before β-blocker initiation and age at start of β-blocker therapy <18 years), treated with a β-blocker were included. Cox regression analyses with time-dependent covariates for β-blockers and potential confounders were used to assess the hazard ratio (HR). The primary outcome was the first occurrence of sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter-defibrillator shock, or syncope. The secondary outcome was the first occurrence of any of the primary outcomes except syncope. RESULTS: We included 329 patients (median age at diagnosis, 12 [interquartile range, 7-15] years, 35% females). Ninety-nine (30.1%) patients experienced the primary outcome and 74 (22.5%) experienced the secondary outcome during a median follow-up of 6.7 (interquartile range, 2.8-12.5) years. Two-hundred sixteen patients (66.0%) used a nonselective β-blocker (predominantly nadolol [n=140] or propranolol [n=70]) and 111 (33.7%) used a β1-selective β-blocker (predominantly atenolol [n=51], metoprolol [n=33], or bisoprolol [n=19]) as initial β-blocker. Baseline characteristics did not differ. The HRs for both the primary and secondary outcomes were higher for β1-selective compared with nonselective β-blockers (HR, 2.04 [95% CI, 1.31-3.17]; and HR, 1.99 [95% CI, 1.20-3.30], respectively). When assessed separately, the HR for the primary outcome was higher for atenolol (HR, 2.68 [95% CI, 1.44-4.99]), bisoprolol (HR, 3.24 [95% CI, 1.47-7.18]), and metoprolol (HR, 2.18 [95% CI, 1.08-4.40]) compared with nadolol, but did not differ from propranolol. The HR of the secondary outcome was only higher in atenolol compared with nadolol (HR, 2.68 [95% CI, 1.30-5.55]). CONCLUSIONS: β1-selective β-blockers were associated with a significantly higher risk for arrhythmic events in symptomatic children with CPVT compared with nonselective β-blockers, specifically nadolol. Nadolol, or propranolol if nadolol is unavailable, should be the preferred β-blocker for treating symptomatic children with CPVT.
引用
- Peltenburg PJ, Kallas D, Bos JM, et al. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2021. PMID: 34874747. doi:10.1161/CIRCULATIONAHA.121.056018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。